RPG Life sciences

25 Jan 2022 , 08:25 PM

For the quarter ending Dec 2021, Net sales (including other operating income) of RPG Life Sciences has increased 7.42% to Rs 115.58 crore compared to quarter ended Dec 2020.

Operating profit margin has jumped from 19.80% to 20.85%, leading to 13.15% rise in operating profit to Rs 24.10 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 20.46% to 19.44%.   Purchase of finished goods cost rose from 14.27% to 19.48%.   Employee cost decreased from 22.93% to 19.68%.   Other expenses rose from 22.30% to 22.85%.   

Other income up 408.33% to Rs 0.61 crore.  PBIDT rose 15.36% to Rs 24.71 crore.  Provision for interest remained nil.  

PBDT rose 15.48% to Rs 24.55 crore.  Provision for depreciation down 6.21% to Rs 3.93 crore.  

Profit before tax grew 20.80% to Rs 20.62 crore.  Provision for tax was expense of Rs 5.99 crore, compared to Rs 4.2 crore.  Effective tax rate was 29.05% compared to 24.60%.

Profit after tax rose 13.68% to Rs 14.63 crore.  

Promoters stake was 72.07% as of 31 December 2021 ,compared to 72.07% as of 31 December 2020 .  

For year-to-date (YTD) results analysis

Net sales (including other operating income) of RPG Life Sciences has increased 13.49% to Rs 336.36 crore.  

Operating profit margin has jumped from 19.32% to 21.66%, leading to 27.20% rise in operating profit to Rs 72.85 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 22.27% to 18.18%.   Purchase of finished goods cost rose from 12.61% to 17.40%.   Employee cost decreased from 23.65% to 20.92%.   Other expenses rose from 22.63% to 23.16%.   

Other income up 183.61% to Rs 1.73 crore.  PBIDT rose 28.85% to Rs 74.58 crore.  Provision for interest fell 34.29% to Rs 0.46 crore.  

PBDT rose 29.63% to Rs 74.12 crore.  Provision for depreciation down 5.34% to Rs 11.88 crore.  

Profit before tax grew 39.46% to Rs 62.24 crore.  Provision for tax was expense of Rs 18.28 crore, compared to Rs 11.55 crore.  Effective tax rate was 29.37% compared to 25.88%.

Profit after tax rose 32.89% to Rs 43.96 crore.  

Promoters stake was 72.07% as of 31 December 2021 ,compared to 72.07% as of 31 December 2020 .  

Full year results analysis

Net sales (including other operating income) of RPG Life Sciences has increased 3.61% to Rs 389.14 crore.  

Operating profit margin has jumped from 15.75% to 17.97%, leading to 18.22% rise in operating profit to Rs 69.93 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 19.69% to 21.76%.   Purchase of finished goods cost fell from 15.36% to 12.78%.   Employee cost increased from 23.84% to 24.02%.   Other expenses fell from 25.60% to 23.71%.   

Other income up 24.66% to Rs 0.91 crore.  PBIDT rose 18.30% to Rs 70.84 crore.  Provision for interest fell 54.86% to Rs 0.79 crore.  Loan funds declined from Rs 6.64 crore as of 31 March 2020 to Rs 2.02 crore as of 31 March 2021.  Inventories rose to Rs 58.33 crore as of 31 March 2021 from Rs 46.61 crore as of 31 March 2020.  Sundry debtors were lower at Rs 57.42 crore as of 31 March 2021 compared to Rs 63.33 crore as of 31 March 2020.  Cash and bank balance rose to Rs 40.75 crore as of 31 March 2021 from Rs 1.11 crore as of 31 March 2020.  

PBDT rose 20.51% to Rs 70.05 crore.  Provision for depreciation rose 0.67% to Rs 16.47 crore.  Fixed assets declined from Rs 91.00 crore as of 31 March 2020 to Rs 87.94 crore as of 31 March 2021.  Intangible assets declined from Rs 41.87 crore to Rs 37.13 crore.  

Profit before tax grew 28.27% to Rs 53.58 crore.  Provision for tax was expense of Rs 13.58 crore, compared to Rs 7.44 crore.  Effective tax rate was 25.35% compared to 20.41%.

Profit after tax rose 37.88% to Rs 40.00 crore.  

Promoters stake was 72.07% as of 31 March 2021 ,compared to 72.07% as of 31 March 2020 .  

Cash flow from operating activities increased to Rs 58.27 crore for year ended March 2021 from Rs 50.17 crore for year ended March 2020.  Cash flow used in acquiring fixed assets during the year ended March 2021 stood at Rs 8.51 crore, compared to Rs 10.74 crore during the year ended March 2020.  

RPG Life Sciences : Standalone Results

 

	2112 (3)	2012(3)	Var (%)		2112 (9)	2012 (9)	Var (%)		2103 (12)	2003 (12)	Var (%)
Sales	115.58	107.60	7.42%		336.36	296.38	13.49%		389.14	375.57	3.61%
OPM (%)	20.85%	19.80%	105 bps		21.66%	19.32%	234 bps		17.97%	15.75%	222 bps
OP	24.1	21.3	13.15%		72.85	57.27	27.20%		69.93	59.15	18.22%
Other inc.	0.61	0.12	408.33%		1.73	0.61	183.61%		0.91	0.73	24.66%
PBIDT	24.71	21.42	15.36%		74.58	57.88	28.85%		70.84	59.88	18.30%
Interest	0.16	0.16	0.00%		0.46	0.70	-34.29%		0.79	1.75	-54.86%
PBDT	24.55	21.26	15.48%		74.12	57.18	29.63%		70.05	58.13	20.51%
Dep.	3.93	4.19	-6.21%		11.88	12.55	-5.34%		16.47	16.36	0.67%
PBT	20.62	17.07	20.80%		62.24	44.63	39.46%		53.58	41.77	28.27%
Share of profit/loss from JV	0.00	0.00	0.00%		0.00	0.00	0.00%		0	0	0.00%
PBT Befor EO	20.62	17.07	20.80%		62.24	44.63	39.46%		53.58	41.77	28.27%
Execptional items	0.00	0.00	0.00%		0.00	0.00	0.00%		0	5.32	LP
PBT After EO	20.62	17.07	20.80%		62.24	44.63	39.46%		53.58	36.45	47.00%
Total Tax	5.99	4.20	42.62%		18.28	11.55	58.27%		13.58	7.44	82.53%
PAT	14.63	12.87	13.68%		43.96	33.08	32.89%		40	29.01	37.88%
Minority Interest	0.00	0.00	0.00%		0.00	0.00	0.00%		0	0	0.00%
Net Profit	14.63	12.87	13.68%		43.96	33.08	32.89%		40.00	29.01	37.88%
EPS (Rs)*	#	#			#	#			24.19	20.10
* EPS is on current equity of Rs 13.23 crore, Face value of Rs 8 Each # EPS is not annualised due to seasonality of business EO: Extraordinary items. EPS is calculated after excluding EO and relevant tax BPS- Basis points LP: Loss to profit PL: Profit to Loss Figures in Rs crore Source: Capitaline Corporate Database

Powered by Capital Market – Live News